Evaluación de la implementación y uso de la Hoja Filtro Preconcepcional como instrumento de atención, Municipio de Tacuba, Departamento de Ahuachapán, El Salvador. 2017

Estudio descriptivo, retrospectivo y de corte transversal, realizado en el municipio de Tacuba, Departamento de Ahuachapán, la unidad de análisis estuvo constituido por los expedientes clínicos y la hoja de filtro preconcepcional registrados en las ecos familiares de municipio de Tacuba correspondientes al año 2017, el universo 112 expedientes y se tomó una muestra de 76. El 58 % de usuarios se encuentran siendo atendidos por médico general graduado, 56% de los establecimientos se encuentra aplicando la hoja filtro preconcepcional, solo 49 % registro factores biológicos, obstétricos y sociales; la calidad de llenado 46 % cumple totalmente con factor biológico, 46 % el factor obstétrico y 38 % el factor social, el procedimiento normatizado de seguimiento solo 15 % cumple totalmente. Las inscripciones preconcepcionales del municipio de Tacuba fueron realizan por médico general graduado y médico en servicio social. La calidad de llenado de la hoja filtro preconcepcional no cumple con los lineamientos establecidos por el ministerio de salud. El cumplimiento del procedimiento normatizado, según el riesgo identificado por el personal de salud, no se está brindando según lo descrito en los lineamientos de Ministerio de Salu

Primer consenso en leucemia linfocítica crónica de la agrupación mexicana para el estudio de la hematología: epidemiología, diagnóstico y tratamiento

La leucemia linfocítica crónica (LLC) es la leucemia crónica menos frecuente en México. En consideración a los avances recientes, a una mejor clasificación pronóstica y a la introducción de nuevas modalidades terapéuticas, la Agrupación Mexicana para el Estudio de la Hematología organizó el primer consenso mexicano en leucemia linfocítica crónica. Este consenso se llevó a cabo en Cancún, Quintana Roo, México, en Septiembre del 2007. Los objetivos de esta reunión fueron actualizar y compartir los conocimientos de la enfermedad entre los especialistas mexicanos, con el fin de mejorar el diagnóstico y el pronóstico de la LLC en México. En el artículo se discute los aspectos clínicos, diagnósticos y terapéuticos de la LLC

Reorganización de los centros de capacitación de la Asociación Fe y Alegría tomo I Diagnóstico

La Asociación Fé y Alegria cuenta con centros de capacitación y cada uno de ellos tiene como objetivo primordial la reorganización de dichos centros, que consiste en el rediseño de los planes de estudios de los sistemas de control administrativo

MICa/b-dependent activation of natural killer cells by CD64+ inflammatory type 2 dendritic cells contributes to autoimmunity.

Primary Sjögren's syndrome (pSS) is an inflammatory autoimmune disorder largely mediated by type I and II interferon (IFN). The potential contribution of innate immune cells, such as natural killer (NK) cells and dendritic cells (DC), to the pSS pathology remains understudied. Here, we identified an enriched CD16+ CD56hi NK cell subset associated with higher cytotoxic function, as well as elevated proportions of inflammatory CD64+ conventional dendritic cell (cDC2) subtype that expresses increased levels of MICa/b, the ligand for the activating receptor NKG2D, in pSS individuals. Circulating cDC2 from pSS patients efficiently induced activation of cytotoxic NK cells ex vivo and were found in proximity to CD56+ NK cells in salivary glands (SG) from pSS patients. Interestingly, transcriptional activation of IFN signatures associated with the RIG-I/DDX60 pathway, IFN I receptor, and its target genes regulate the expression of NKG2D ligands on cDC2 from pSS patients. Finally, increased proportions of CD64hi RAE-1+ cDC2 and NKG2D+ CD11b+ CD27+ NK cells were present in vivo in the SG after poly I:C injection. Our study provides novel insight into the contribution and interplay of NK and cDC2 in pSS pathology and identifies new potential therapy targets.S

El hueso, la obesidad y su interacción endocrina

La asociación entre la obesidad y la densidad mineral ósea ha sido un punto controversial al momento de establecer si existe una asociación positiva o negativa entre las mismas. Diversos estudios han propuesto que la obesidad es un factor protector del hueso, debido a la tensión mecánica dada por el peso corporal en la remodelación ósea. Otros estudios plantean que la relación es mucho más compleja debido a que el tejido adiposo y los osteoblastos provienen de líneas germinales comunes. Además, el adipocito tiene la capacidad de secretar diversas moléculas, entre ellas las adipocinas. Adicionalmente, el tejido adiposo es una de las principales fuentes de aromatasa, esto lo involucra en la conversión de andrógenos a estrógenos, que juegan un papel importante en el mantenimiento de la homeostasis ósea. Por lo tanto, se ha planteado el hueso como órgano blanco de diversas vías endocrinas y, a su vez, se considera un órgano endocrino que puede afectar otros órganos cuando está alterado. Por otra parte, se ha visto que la resistencia a la insulina en el contexto de la obesidad está asociada con inflamación crónica de bajo grado, deterioro funcional de órganos y alteración del metabolismo energético, que impacta la remodelación ósea.   Abstract There is controversy over the effect of obesity in bone mineral density. Several studies have proposed that obesity is a protective factor of the bone by the mechanical tension that favors the bone remodeling. However, other studies suggest that this relationship is more complex because both tissues come from a common germ line; emphasizing that the adipocyte secretes diverse molecules, among them adipocinas. In addition, adipose tissue has aromatases that convert androgens into estrogens, having an importance in bone homeostasis. Therefore, the bone has been raised as a target organ of various endocrine pathways, which may affect other organs when it is altered. On the other hand, it has been shown that insulin resistance in the context of obesity is associated with chronic low-grade inflammation, functional impairment of organs and impaired energy metabolism, which impacts bone remodeling

Advances in Xmipp for cryo-electron microscopy: from Xmipp to Scipion

Xmipp is an open-source software package consisting of multiple programs for processing data originating from electron microscopy and electron tomography, designed and managed by the Biocomputing Unit of the Spanish National Center for Biotechnology, although with contributions from many other developers over the world. During its 25 years of existence, Xmipp underwent multiple changes and updates. While there were many publications related to new programs and functionality added to Xmipp, there is no single publication on the Xmipp as a package since 2013. In this article, we give an overview of the changes and new work since 2013, describe technologies and techniques used during the development, and take a peek at the future of the package

Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines

Background: Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice. In other parts of the world, extracts from both regions and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT guideline (GUIMIT 2019) searching for compromises between both schools. Methods: Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evaluating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of various German-speaking medical societies (2014), and the US Practice Parameters on Allergen Immunotherapy 2011. We formulated clinical questions and based responses on the fused evidence available in the MRGs, combined with local possibilities, patient's preference, and costs. We came across several issues on which the MRGs disagreed. These are presented here along with arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version, see Supplementary data) concluded the following: Results: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing complementary tests (challenges, in vitro testing and molecular such as species-specific allergens) might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning the correct subcutaneous AIT dose for compounding vials according to the US school: dosing tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing high with low protease extracts. When using European extracts: the manufacturer's indications should be followed; in multi-allergic patients 2 simultaneous injections can be given (100% consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50–200% of the monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical suggestions on non-evidence-existing issues, developed with a simplified Delphi method, is added. Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we used online tools for this in Mexico. Conclusions: Countries where European and American AIT extracts are available should adjust AIT according to which school is followed